-
Mashup Score: 2Updated Analysis of Nivolumab Plus Ipilimumab Combos Highlights Long OS for Advanced Melanoma - 2 year(s) ago
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Fast Track Designation Granted to Novel Immunostimulant 7HP349 in Anti–PD-1 Resistant Melanoma - 2 year(s) ago
7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A recent study found women had a 2-fold higher mortality risk than men when being treated with immune checkpoint inhibitors for advanced melanoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adjuvant Pembrolizumab Significantly Improved DMFS Vs Placebo in Resected Stage IIB/C Melanoma - 2 year(s) ago
The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Findings from a study indicated that patients with melanoma who had a high fiber diet experienced better responses to immunotherapy.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Cosibelimab Achieves Promising Responses in Metastatic Cutaneous Squamous Cell Carcinoma - 2 year(s) ago
Patients with metastatic cutaneous squamous cell carcinoma who were treated with cosibelimab experienced a positive objective response rate.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Tebentafusp for Patients With Metastatic Uveal Melanoma and HLA-A*02:01 - 2 year(s) ago
Tebentafusp has been approved by the FDA based on results of the phase 3 IMCgp100-202 trial for patients harboring HLA-A*02:01 with metastatic uveal melanoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma. #melcsm | @wolchokj https://t.co/F1eWIpAcUx